August 6, 2024

Profound Research Accelerates Growth Trajectory with New Chief Commercial Officer 

Profound Research, a leading clinical trial site network, today announced the key leadership appointment of Michael Shipton as Chief Commercial Officer, a move aimed at driving innovation and continued growth.  

Shipton brings extensive experience to his new role. He most recently served as Chief Commercial Officer at Science 37, where he led transformative initiatives and overhauled their go-to-market strategy, resulting in increased market competitiveness. As a proven commercial strategist, Shipton has over three decades of experience designing, implementing, and delivering customized business solutions. All in all, Shipton has a broad track record of success in steering large global teams to address intricate business challenges. 

“I am honored to join an organization that understands how commercial growth in our vertical market can directly enrich patient lives by expanding access to innovative treatments and advancing scientific progress,” said Shipton.  

Lora Parahovnik, PhD, Chief Executive Officer of Profound Research, shared her excitement about the appointment, stating, "We are delighted to welcome Michael Shipton as our Chief Commercial Officer. His expertise and leadership will be pivotal in advancing Profound Research as an industry leader focused on medical innovation and enhancing patient access to treatments.” 

About Profound Research 

Profound Research is an integrated clinical research network comprising trial sites embedded into independent physician practices. With a mission to expand access to clinical research for community patients and offer more therapeutic options to community physicians, Profound Research operates across Southern California, the Detroit metropolitan area, and is expanding nationwide. The company boasts a team of experienced research professionals dedicated to providing high-quality clinical research support to physicians and their patients. 

July 3, 2024

Eli Lilly Achieves FDA Approval of Kinsunla™ 

Celebrating a Milestone in Alzheimer's Treatment

Profound Research extends our heartfelt congratulations to our sponsor partner, Eli Lilly, on the recent approval of Kinsunla™ by the Food and Drug Administration (FDA). This groundbreaking development marks a significant step forward in the battle against Alzheimer's disease, providing new hope to individuals and their families affected by this debilitating condition. 

To learn more about Kinsunla™, read the full release at Eli Lilly. 

Kinsunla™, now the second drug on the U.S. market aimed at slowing the progression of early-stage Alzheimer's, has demonstrated remarkable efficacy. According to Eli Lilly, the drug slowed cognitive and functional decline by up to 35% compared to placebo at 18 months in its pivotal Phase 3 study. Furthermore, it reduced participants' risk of progressing to the next clinical stage of the disease by up to 39%. These promising results underscore the potential of Kinsunla™ to transform the landscape of Alzheimer's treatment. 

Profound Research at Neurology Center of Southern California (NCSC), under the leadership of Principal Investigator, Benjamin Frishberg, MD, is proud to serve as a site for the TRAILBLAZER program. Dr. Gregory Sahagian, CEO of NCSC and Chief Scientific Officer for Profound Research, emphasized the significance of this achievement, stating, "This is why we do clinical research. This is an advancement over previously approved therapies and a step forward in our fight to overcome Alzheimer’s Disease. Our patients have been enrolled in the study and were provided the opportunity for early access to a disease modifying therapy." 

April Tenorio, CCRC, Clinical Research Site Manager for Profound Research at NCSC, sharing her appreciation, stating: "As Kisunla™ steps into the market, the lasting impact of our site stands strong, showcasing the importance of teamwork, determination, and advancements in science. It serves as a reminder that behind every clinical research setting, there exists the opportunity to make a difference in people’s lives and shape the course of medical advancements. It has been a remarkable journey that we are all proud to be a part of!" 

This most recent achievement aligns with Profound Research's mission of contributing to continued innovation in medicine while improving health outcomes. Our involvement in the development and approval of Kinsunla™ highlights our commitment to progress and our dedication to supporting advancements that enhance the quality of life for patients.  

Once again, we commend Eli Lilly on this momentous development. With this promising new treatment, clinical research is paving the way for a brighter future for patients with Alzheimer's, bringing hope and potential benefits to those affected by this challenging disease.

June 28, 2024

Dedicated to Integrity – a Spotlight on Susana Wallace of Southern California 

At Profound Research, we are dedicated to delivering clinical trials and advanced therapies to diverse communities across the nation. Today, we are thrilled to feature insights from Susana Wallace, a Patient Recruitment Specialist in Southern California. As a Native American and lifelong San Diegan, Susana’s passion, dedication, and alignment with our core values play a crucial role in connecting cutting-edge medical advancements with the communities that need them most, making her an invaluable asset to our team. 

What is your role at Profound research and how long have you been doing it? 

For the better part of the last year, I have served as aPatient Recruitment Specialist at Profound Research for the Neurology Center of Southern California (NCSC), Dermatology Medical Group of North County (DMG) and Arthritis Consultants of North County (ACNC).  

Before coming to Profound, I was a research coordinator for University of Southern California at San Diego (UCSD) School of Medicine. I have also worked for the County of San Diego Public Health Department, as well as the California Department of Public Health (CDPH), doing surveillance, epidemiology, and communicable disease investigations. 

Please tell us a little about you personally. 

Born and raised, I am a Native San Diegan- I grew up in Valley Center, spending time between La Jolla Indian Reservation and Rincon Indian Reservation. I am married (19 years) and have two kids. We spend a lot of time outdoors hiking and going to the beach. I personally love running, gardening, and spending time with my family. 

What is your favorite part of your role at Profound Research? 

My favorite part of my role is connecting with the patients; listening to their stories and finding out what brings them to Profound. Most of all, getting them scheduled for a visit for one of our clinical studies is extremely rewarding. 

What is one thing all people should know about clinical research with Profound Research?  

People should know that when they choose to come to Profound, they will be well taken care of. 

Of our values - Compassion, Efficiency, Progress, and Integrity, what is one that resonates with you in your current role and tell us a time it applied to an interaction with a patient or co-worker? 

While compassion comes to mind, I still would have to say it is integrity. Integrity strongly resonates with me. Coming from a culture that is deeply affected by our healthcare system, public health programs, and past research practices, my community is suspicious. Integrity is a personal responsibility and obligation I have to all our patients, and especially those who may not have access to appropriate care. Some examples would be patients under-represented in research, uninsured and unable to access care, and under- served populations that do not know how to navigate the healthcare system. Although integrity comes in all forms, for me, it comes in the way we offer and extend services to patients. I want to do all I can to remove any fears or suspicions they may have. 

From working in academia and government, I have learned one thing - when doing research, it is so important to have a diverse team. Patients want to see someone that looks like them, can relate to them and most importantly, understand them. Profound Research offers that to the communities we are currently trying to reach and that is a form of INTEGRITY. Having a research team that looks like the population they are serving is so special. 

I am so fortunate to have found a space at Profound Research where I am at peace with the work I am doing. 

To learn more about clinical trials at Profound Research by click here.

April 18, 2024

Profound Research: Spotlight on Barry Feldman, M.D., Internal Medicine 

At Profound Research, we're committed to highlighting the individuals who are advancing medical science and patient care through their work in clinical research. Today, we're excited to share insights from Dr. Barry Feldman, an Internal Medicine provider, and Principal Investigator at Profound Research. Dr. Feldman practices at Michigan Healthcare Professionals (MHP) TriAtria, a multidisciplinary health practice and research site in Farmington Hills, MI. MHP TriAtria, which encompasses a broad spectrum of medical indications including neurology, endocrinology, cardiovascular, and internal medicine, attends to approximately 36,000 annual patient visits. Join us as we explore Dr. Feldman's journey in clinical research, gaining valuable insights into his experiences and contributions to the field.  

What led you to clinical research? 

Dr. Feldman: My first endeavor into clinical research was at Northwestern University. I was working nights as a young graduate student and going to school during the day. I was working in the automated chemistry lab, supervising the night shift. We were running samples from the ongoing Framingham Cholesterol Study. Although the study began in 1948, we were still following participants in the early 1970’s. We had developed better testing abilities and computer technology. This study went on to change the way we looked at lipids and heart disease.   

While there, I was recruited onto the Renal Transplant team, working in organ harvesting and preservation. This was an exciting and relatively new field with new and ongoing research. Tissue typing was in its early stages and far from perfect. HLA typing was standard practice.  Northwestern had begun working on Mixed Lymphocyte Culture research as a confirmatory methodology. I became involved in the bench and clinical research - following organs from donor to recipient and witnessed firsthand how this changed lives. This experience was both exciting and incredibly rewarding. 

2. What is your favorite part about working in clinical research? 

Dr. Feldman: It’s all about the process - following the research process from being presented with a problem, to the concept of a possible solution, the challenge of proving it, and the real-life implementation. This was never more evident than in the past 3 years. During the COVID pandemic we worked at warp speed, developing testing, immunization, and therapeutic processes, that did not exist previously. 

3. Do you have a particular success story that stuck with you? 

Dr. Feldman: My favorite research period has been the past three years. On March 22,2020, like all the medical community, we went to war against COVID. I felt that I had to do something. With the help of my wife Lesley, and a small, dedicated crew, I put up a tent and trailer in the parking lot behind my medical building. Over the next two years, we went on to test over 160,000 lives and deliver 18,000 vaccines. We also treated those patients who were sick, keeping 16,000 out of ER’s and hospitals. We worked with research partners on Monoclonal Antibody infusion, for which I was one of the PI’s.  This was an example of experiencing research in hyperdrive. 

4. What would you want people to know about clinical research? 

Dr. Feldman: Clinical research has and continues to make lives better and longer. When I was a medical student, the life expectancy of a man was 60 years. Today, it’s 78 years. In my lifetime, I have been blessed to see multiple infectious diseases controlled, devices and procedures that sustain, improve, and prolong life, as well as drugs that enable better quality and duration of life. All of this is the result of dedicated individuals doing research with the imagination to develop new paradigms. 

5. What are some hobbies/interests of yours outside of clinical research? 

Dr. Feldman: In addition to my dedication to clinical research, I’m an avid golfer and find solace and joy in time spent with my family. 

Beyond personal pursuits, my passion for teaching extends to shaping the minds of future physicians. As an educator, I am privileged to impart knowledge, instill values, and inspire the next generation of healthcare professionals. Witnessing their growth and seeing the spark of curiosity ignite within them is immensely rewarding, reaffirming my commitment to perpetuating excellence in medical practice and research. 

Subhead:  

In Closing 

As we conclude this spotlight on Dr. Feldman, we are reminded of the profound impact that passionate individuals can have on our collective well-being. We encourage you to stay engaged with Profound Research as we continue to spotlight those who shape the future of science and healthcare. We eagerly anticipate sharing more visionary leaders in our upcoming editions of the Profound Research Spotlight Series. 

April 17, 2024

Exploring Promising Avenues in Neurological Research

Skin Biopsy as a Potential Diagnostic Tool for Synucleinopathies Exploring Promising Avenues in Neurological Research

The groundwork for a notable advancement in establishing new diagnostic procedures for Synucleinopathies through skin biopsy has been laid by a recent collaboration of 28 research organizations across the United States. Among the participants in this study was The Neurology Center of Southern California, a respected member of the Profound Research site network. 

Central to this study is a fundamental question: Can phosphorylated α-synuclein be detected in individuals with synucleinopathies such as Parkinson's disease (PD), multiple system atrophy (MSA), dementia with Lewy bodies (DLB), and pure autonomic failure (PAF) through skin biopsy? The findings, revealed through a thorough cross-sectional analysis of 428 participants, are indeed promising. 

According to the study, a significant proportion of individuals with PD, MSA, DLB, and PAF exhibited the presence of cutaneous phosphorylated α-synuclein, as detected by skin biopsy. The numbers were particularly notable: 92.7% for PD, 98.2% for MSA, 96.0% for DLB, and an impressive 100% for PAF. These findings shed light on a hopeful avenue for improving diagnostic accuracy in neurological disorders. 

Gregory Sahagian, CEO of the Neurology Center of Southern California and Chief Scientific Officer for Profound Research, shares his perspective on this groundbreaking endeavor, remarking, "The implications of these findings are profound. They offer hope for earlier and more accurate diagnoses and open doors to potential breakthroughs in treatment strategies." 

However, amidst the excitement stirred by these findings, it's crucial to proceed with caution. As with any scientific inquiry, further validation and exploration are necessary. While this study presents compelling evidence of the effectiveness of skin biopsy in detecting phosphorylated α-synuclein, there remains a pressing need for broader research in unselected clinical populations to confirm these findings and fully understand their clinical implications. 

In summary, the emergence of skin biopsy as a potential diagnostic tool for synucleinopathies represents a promising development in neurological research. As we navigate this evolving landscape, we remain steadfast in our pursuit of bringing about meaningful advancements in healthcare for the communities that stand to benefit the most. 

For a full review of the study and it’s participants, visit https://jamanetwork.com/journals/jama/article-abstract/2816441  

JAMA is a peer-reviewed medical journal published by the American Medical Association. 

April 3, 2024

Profound Research: Spotlight on Paul Lizotte, D.O., Internal Medicine 

At Profound Research, we're committed to highlighting the individuals who are advancing medical science and patient care through their work in clinical research. Today, we're excited to share insights from Paul Lizotte, an Internal Medicine provider and Principal Investigator at Profound Research. Dr. Lizotte practices at Seaside Medical Group (SMG) in Oceanside, CA. The clinic, which encompasses a broad spectrum of medical indications, including vaccine and internal medicine, consistently attends to approximately 75 patients every month with expanding access due to the recent addition of a new PA-C. Join us as we explore Dr. Lizotte's journey in clinical research, gaining valuable insights into his experiences and contributions to the field.  

What led you to clinical research? 

Dr. Lizotte: My journey into clinical research stemmed from my background in academic institutions. Throughout my career, I've found fulfillment in conducting trials and contributing to medical literature through published papers. The opportunity to actively engage in the advancement of medical knowledge has always been a driving force for me. 

In addition to my academic pursuits, I am deeply committed to bringing cutting-edge therapies to my patients. Clinical research allows me to bridge the gap between medical innovation and patient care, which is incredibly rewarding. 

2. What is your favorite part about working in clinical research? 

Dr. Lizotte: My favorite aspect of clinical research is undoubtedly the opportunity to bring new therapies to patients who may not otherwise have access to them. Witnessing the tangible impact of these treatments on individuals' lives is profoundly gratifying. Knowing that I have played a part in improving patient outcomes and quality of life is what fuels my passion for this work. 

Moreover, collaborating with fellow researchers and healthcare professionals in the pursuit of medical advancement is both intellectually stimulating and fulfilling on a personal level. 

3. Do you have a particular success story that stuck with you? 

Dr. Lizotte: One success story that remains etched in my memory involves my involvement in a trial for an oncology medication called Bexar. This medication proved to be a game-changer for many patients battling cancer, offering them newfound hope and improved prognoses. 

Witnessing the transformative impact of Bexar on patients' lives was truly remarkable. Seeing individuals regain their vitality reaffirmed my dedication to clinical research and its potential to make a meaningful difference in healthcare. 

4. What would you want people to know about clinical research? 

Dr. Lizotte: One misconception that I often encounter is the belief that clinical research is fraught with deceit or serves as a platform for promoting dubious treatments. However, as a healthcare provider and researcher, I can attest to the rigor and integrity that underpins reputable clinical trials. 

It's crucial for people to understand that clinical research is conducted with the utmost ethical standards and patient safety as top priorities. As a physician, I am committed to transparency and honesty in my practice, and I would never endorse a treatment that I believe to be harmful or ineffective. 

Ultimately, clinical research serves as a vital conduit for bringing forth medical advancements that have the potential to positively impact countless lives. By participating in clinical trials, patients not only contribute to the advancement of science but also gain access to innovative treatments that may offer hope where conventional therapies fall short. 

5. What are some hobbies/interests of yours outside of clinical research? 

Dr. Lizotte: Outside of my professional endeavors, I am an avid enthusiast of archaeology, particularly ancient civilizations. I've had the privilege of participating in archaeological digs in Italy and Switzerland, where I've immersed myself in the exploration of Etruscan tombs. 

Unearthing precious artifacts and unraveling the mysteries of ancient cultures has been a deeply enriching experience for me. It serves as a welcome respite from the rigors of clinical research and allows me to indulge in my passion for history and discovery. 

Subhead:  

In Closing 

As we conclude this spotlight on Dr. Lizotte, we are reminded of the profound impact that passionate individuals can have on our collective well-being. We encourage you to stay engaged with Profound Research as we continue to spotlight those who shape the future of science and healthcare. We eagerly anticipate sharing more visionary leaders in our upcoming editions of the Profound Research Spotlight Series. 

March 7, 2024

Profound Research: Spotlight on Faisal Musa, M.D., Medical Oncologist

At Profound Research, we strive to highlight the remarkable individuals who contribute to the advancement of medical science and patient care through clinical research. Today, we have the privilege of sharing insights from Faisal Musa, M.D., a Medical Oncologist and Profound Research Principal Investigator at Michigan Healthcare Professionals (MHP) located in Dearborn. Let's delve into Dr. Musa's journey in clinical research, his insights, and his contributions to the field.

What led you to clinical research?

Oncology is a dynamic and ever-evolving field that presents continuous challenges. My passion for making a meaningful difference in patients' lives, coupled with the opportunity to explore novel treatments and therapies, drew me towards clinical research. Being at the forefront of discovering new ways to combat cancer and improve outcomes for patients is immensely fulfilling.

What is your favorite part about working in clinical research?

One of the most exhilarating aspects of clinical research is the opportunity to venture into the unknown. Exploring the efficacy and potential side effects of new medications and treatments not only expands our understanding but also holds the promise of revolutionizing patient care. Additionally, being involved in pioneering therapies that could shape the future of medicine is truly rewarding.

Do you have a particular success story that stuck with you?

Indeed, I have a memorable success story involving a Multiple Myeloma patient who has been on Revlimid successfully for over 10 years, with stable disease. Witnessing the tangible impact of innovative treatments on patients' lives reaffirms the importance of clinical research and motivates me to continue pushing boundaries in oncology.

What would you want people to know about clinical research?

It's crucial for individuals to understand that while clinical trials may not offer immediate solutions for every condition, they play an indispensable role in advancing medical knowledge and developing new therapies. By participating in clinical trials, patients not only contribute to the collective effort in finding better treatments but also gain access to potentially groundbreaking interventions.

What are some hobbies/interests of yours outside of clinical research?

Outside of my professional endeavors, I am an avid soccer enthusiast. Engaging in sports not only provides a welcome respite from the demands of clinical research but also promotes physical well-being and a balanced lifestyle.

Is there any other information you’d like sponsors or patients to know about you?

As a community hematologist and oncologist, I am committed to providing comprehensive care across a wide spectrum of hematological disorders and solid tumors. Additionally, serving as a System Professor at Wayne State University and holding the position of Section Chief of Medical Oncology at Corewell Health System in Dearborn underscores my dedication to academic excellence and clinical leadership.

In Closing

The expertise, dedication, and groundbreaking research of Dr. Musa have not only elevated the field of medical oncology but have also touched the lives of countless patients. His insights shed light on the transformative potential of clinical trials and the profound impact they can have on individuals battling cancer.

As we conclude this spotlight, we are reminded of the profound impact that passionate individuals can have on our collective well-being. We encourage you to stay engaged with Profound Research as we continue to spotlight those who shape the future of science and healthcare. We eagerly anticipate sharing more visionary leaders in our upcoming editions of the Profound Research Spotlight Series.

February 8, 2024

Profound Research Charts Exciting Growth Path with Hire of CEO and Strategic Promotions of Key Leadership Roles

Nashville, TN - [February 8, 2024] - Profound Research, a leading clinical trial site network, today announced key leadership appointments aimed at driving innovation and continuing growth. These appointments include Lora Parahovnik, Ph.D., MBA, as Chief Executive Officer, along with the internal promotions of Marty Anderson to Chief Operations Officer and Christopher Church to Chief Commercial Officer.

Dr. Parahovnik brings extensive experience to her new role. She most recently served as CEO at Accel Research Sites Network where her teams set industry benchmarks for patient-centric clinical research within modern healthcare ecosystems. 

“I am honored to join an organization with a vision deeply rooted in improving patient lives, ensuring access to innovative treatments, and propelling scientific and medical progress,” said Parahovnik.  “It is a privilege to lead a team whose mission aligns seamlessly with my own values and aspirations.” 

Marty Anderson, promoted to Chief Operations Officer, has been a pivotal figure in Profound's journey, spearheading operations since the company's inception. Her 30-year experience in the clinical trial industry and dedication to operational excellence position Profound for continued growth in both quality and market presence. 

Christopher Church, promoted to Chief Commercial Officer, brings a wealth of experience in building successful commercial teams and driving business development initiatives within the clinical trial industry. His strategic leadership has been focal in expanding Profound's therapeutic area expansion and driving revenue growth. 

Dr. Jonathan Feldstein, President and co-founder of Profound Research, expressed his enthusiasm for these appointments, saying, "We are thrilled to welcome Lora Parahovnik as our CEO and to announce the well-deserved promotions of Marty Anderson and Christopher Church. Their combined ability and leadership will be instrumental in driving Profound Research forward as an industry leader dedicated to medical innovation and patient access to those treatments.”  

About Profound Research

Profound Research is an integrated clinical research network comprising trial sites embedded into independent physician practices. With a mission to expand access to clinical research for community patients and offer more therapeutic options to community physicians, Profound Research operates across Southern California, the Detroit metropolitan area, and is expanding nationwide. The company boasts a team of experienced research professionals dedicated to providing high-quality clinical research support to physicians and their patients. 

For inquiries, please contact:

info@profoundresearch.io 

Profound Research LLC 

January 31, 2024

Enhancing Cardiovascular Research: Profound’s Collaborative Approach with MHP CAVA

Clinical research plays a crucial role in advancing medical knowledge, with sponsors and contract research organizations frequently facing the challenges posed by the intricacies of cardiovascular studies. One prevalent challenge is the limited availability of US-based sites, prompting sponsors to seek new, community-based alternatives. Profound Research empathizes with these challenges and has developed a thoughtful approach to simplify a comprehensive range of clinical studies, including cardiovascular.

Understanding Sponsor Challenges:

Sponsors navigating the intricate landscape of cardiovascular research often encounter hurdles due to a restricted US-based site footprint. This saturation poses challenges in conducting studies efficiently and reaching diverse patient populations. Profound Research acknowledges this dilemma and has tailored its model to provide sponsors with a solution that overcomes typical challenges and aligns with their goals.

The Key Solutions: Community-based Partnerships and Central Support

To solve these challenges in the cardiovascular space, Profound Research, whose network also includes MHP TriaAtria and Southern California Heart Specialists, has formed a partnership with Michigan Healthcare Professionals Cardiology and Vascular Associates (MHP CAVA). Situated at 42557 Woodward Avenue, Suite 200, Bloomfield Hills, MI 48304, MHP CAVA serves a diverse range of populations just 30 minutes outside of Detroit.

One: Leadership at MHP CAVA

At the forefront of this collaborative effort are two highly experienced interventional cardiologists: Abdul R. Halabi, M.D., FACC and Kirit Patel, M.D., FACC. With a collective experience exceeding fifty years, these providers have dedicated themselves to advancing cardiovascular medicine and have played pivotal roles as principal or sub-investigators in over seventy research studies. Their commitment to patient well-being and innovation aligns seamlessly with Profound's mission of actively connecting patients to advanced therapeutic options in their own communities.

Two: Profound's Comprehensive, Centralized Support

Beyond establishing strategic relationships and connecting sponsors with community-based providers, Profound Research offers central support to sponsors, covering crucial aspects such as technology, feasibility, budget and contract, regulatory and startup processes, as well as quality control. This centralized support ensures that sponsors can concentrate on the scientific aspects of their studies while Profound handles the logistical and administrative challenges, resulting in expedited progress and truncated timelines from start-up on through the fruition of clinical advancements. To learn more about Profound's approach to centralized support, click here.

Taking Action: How Sponsors Can Benefit

To get started, Profound Research invites sponsors to include any one of our four cardiovascular research sites in ongoing and planned feasibility processes for cardiovascular studies. By doing so, sponsors will access a largely untapped patient population along with the expertise of our highly skilled team at MHP CAVA. We look forward to discussing with innovators in the cardiovascular space how Profound’s cardiovascular sites can tailor support to specific research needs.

Conclusion

In cardiovascular research, Profound Research emerges as a preferred collaborative partner, offering thoughtful solutions to sponsors seeking efficient and impactful studies. The partnership with MHP CAVA, coupled with Profound's comprehensive support, creates an inviting opportunity for sponsors to advance their research goals seamlessly. By engaging with Profound's feasibility team at feasibility@profoundresearch.io, sponsors can take the first step toward transforming their cardiovascular research initiatives.

January 4, 2024

Bridging the Gap: How Profound is Harnessing the Power of Diversity for Robust Clinical Trial Outcomes

Byline: Erem Latif

Over the past 12 years, there has been a growing emphasis on exploring the social determinants of health. Our comprehension of how economic stability, community dynamics, access to resources, and the quality of education, among various other nuanced elements, significantly influence an individual's health, quality of life, and overall outcomes has substantially expanded. The U.S. Office of Disease Prevention and Health Promotion has even launched the Healthy People 2030 plan to help address the upstream factors impacting health disparities.

Futhermore, personalized medicine, the understanding that variables like genetics, environment, and lifestyle play a direct role in shaping an individual's response to identical treatment regimens or vaccines, is leading to an evolution in healthcare. Ultimately, each person's unique lived experience, impacted by environment, ethnicity, age, gender, and other societal factors becomes the foundation for their physical and mental well-being.

The Crucial Role of Diversity in Patient Recruitment for Clinical Research Studies

When applied to clinical research, the recognition of social determinants of health amplifies their impact on diverse lived experiences. The imperative arises for our society to ensure the effectiveness of new treatments across all population subgroups. However, recent data reveals a predominant participation of white individuals in clinical research endeavors.

References:

- US Food and Drug Administration 2020 drug trials snapshot. Summary report.

https://www.fda.gov/media/145718/download

- US Food and Drug Administration. Enhancing the diversity of clinical trial populations—eligibility criteria, enrollment practices, and trial designs guidance for industry.

https://www.fda.gov/regulatory-information/search-fda-guidance-documents/enhancing-diversity-clinical-trial-populations-eligibility-criteria-enrollment-practices-and-trial

Advancements in healthcare underscore the variability in how individuals experience the same disease, with certain medications exhibiting distinct efficacy across diverse populations, ages, or genders. It is crucial that safety and efficacy data from clinical research encompass the experiences of all subgroups before treatments receive approval and enter the market. The dearth of diversity in clinical research poses the risk of rendering medications and treatments less effective for specific subgroups.

A notable illustration of this discrepancy is evident in the varying efficacy of beta blockers and ACE inhibitors between individuals of White European and Black African ancestry.

Reference:

https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.107.704023?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed

More recently, during the Covid-19 pandemic, preliminary findings from the trial of Moderna’s Covid-19 vaccine were based on a predominantly White participant population—not an adequately representative sample of the U.S. population.

Defining Diversity in Patient Recruitment for Clinical Trials: Profound Research's Perspective

Examining Profound Research's approach to defining diversity involves delving into the specific criteria and considerations we employ. Our definition encompasses factors such as age, gender, ethnicity, socioeconomic status, and other relevant parameters. We adhere to validated (?) guidance from esteemed sources like the NIH and the FDA, utilizing a comprehensive framework that goes beyond conventional criteria. This includes incorporating nuanced parameters that profoundly impact the lived experience of individuals. Our commitment extends further to considering typically underrepresented therapeutic areas or conditions and addressing data gaps across various subpopulations.

References:

https://www.nimhd.nih.gov/resources/understanding-health-disparities/diversity-and-inclusion-in-clinical-trials.html

https://www.fda.gov/consumers/minority-health-and-health-equity/clinical-trial-diversity

Strategies Employed by Profound Research to Enhance Diversity in Patient Recruitment Across Demographic Groups

Profound Research is committed to revealing the proactive measures and approaches undertaken to actively recruit and engage diverse patient populations, with the ultimate goal of ensuring a representative sample in clinical studies.

Our approach is multifaceted, commencing with a focus on geography. We strategically establish partnerships with sites in urban and metro areas. Building upon this foundation, we delineate geographic regions, positioning our sites as central hubs. Recognizing that potential participants prefer local accessibility, we aim to minimize travel distances for involvement in clinical trials or physician visits. Additionally, we actively immerse ourselves in these communities, participating in health fairs and providing screenings and related services. Through the dissemination of information and resources, our objective is to empower local patients, fostering a basis of trust within these communities. We envision the cultivation of this trust as a standard practice, allowing us to recruit patients from diverse backgrounds effectively.

Significance of Geographic Diversity in Patient Recruitment

Centrally addressing the importance of geographic diversity, this discussion emphasizes its pivotal role in advancing the overarching diversity objectives within clinical research studies. The exploration extends to encompass regional health variations, cultural distinctions, and the profound impact of local demographics on the outcomes of the studies.

Furthermore, the positioning of research sites in diverse regional hubs such as San Diego, Los Angeles, and Detroit, paired with diversity of staffing directly contribute to enhancing trial diversity. Recent findings from a white paper by Tufts Center for the Study of Drug Development underscore a significant correlation between the diversity of research site staff and the diversity observed among patients involved in clinical trials.

References: https://medicine.tufts.edu/news-events/news/increase-diversity-clinical-trials-first-increase-staff-diversity

In light of this insight, Profound Research strategically chooses urban areas characterized by vibrant and diverse populations. By establishing partnerships with sites committed to effective practices for engaging and enrolling diverse patients—bolstered by robust infrastructure and streamlined processes—the company is actively contributing to the delivery of expanded treatment options to those who need them most.

Strategies in Overcoming Diversity Challenges for Credible and Relevant Study Findings

Overcoming the primary challenge of recruiting diverse patient populations, particularly centered around trust, is a focal point for Profound Research. Over the years, a pervasive lack of trust has been observed among minority patients within the healthcare system, with historical incidents such as the syphilis research conducted by the U.S. Public Health Service at the Tuskegee Institute of Alabama exemplifying this issue. Language poses a secondary barrier, underscoring the importance of effective communication tailored to patients' comprehension levels regarding potential treatment benefits, possible side effects, and the significance of adherence to treatment regimens. Additionally, logistical hurdles like transportation, employment commitments, and childcare responsibilities can hinder participation.

To address these challenges comprehensively, Profound Research offers external support mechanisms to its research sites, allowing them to concentrate on patient care. Community events held at centers, religious organizations, and farmers markets play a crucial role in building and fostering a relationship of trust with diverse populations. The organization's dedicated team of patient engagement specialists consistently provides education and information to local patient communities, addressing disparities arising from limited access to education. Moreover, Profound has developed concierge-style patient support services, aiding with transportation, childcare, and other potential impediments that might otherwise deter diverse populations from participating in clinical trials.

Conclusion

At its core, individual health is shaped by the intertwined dynamics of physical and mental well-being, profoundly influenced by the lived experience and social determinants of health. Profound Research, by prioritizing diversity and ensuring access to treatment options for all, and through strategic partnerships with like-minded practices, is actively transforming the landscape of clinical research. This commitment aligns with the understanding that addressing diversity challenges and fostering inclusivity not only enhances the credibility and relevance of study findings but also contributes to a more comprehensive and equitable healthcare future.

About the Author: Currently serving as the Senior Director of Patient Recruitment and Engagement for Profound Research, Erem Latif, MS, MBA, is an innovative healthcare leader with experience in leveraging operational excellence, client relationship management and strategic marketing and communications to elevate brand, drive patient engagement, and optimize clinical outcomes. Furthermore, Erem offers a deep understanding of complex industry and proven methodologies to improve results for providers, health systems, and payers.

Profound Research LLC, 1213 5th Avenue North, Nashville, TN 37208